简介：摘要目前国内新型冠状病毒病疫情总体呈现散发状态，防范疫情任务仍然艰巨。近距离治疗(BT)在肿瘤患者治疗中起着重要的作用，在部分恶性肿瘤放疗过程中，BT不能被替代也不可过度延迟。而对于疫情期间BT推荐或指导的相关报道较少。本文总结国内外可检索到的较少几篇关于疫情期间BT的推荐，结合吉林大学中日联谊医院放射治疗科在前期疫情期间的工作经验，希望可以给同行们提供疫情期间恶性肿瘤高剂量率BT的参考。

简介：摘要目的回顾性分析新型冠状病毒在康复患者不同标本取样(咽拭子、痰液及粪便)中的分布情况，以提供更为可靠的出院依据，减少患者出院后复发传染的风险。方法采用实时荧光定量RT-PCR方法，对78例患者出院前的咽拭子和痰液单次配对采样，54例患者两次配对取样(间隔1～5 d)，检测病毒在两种类型标本中的检出情况；观察6例出院患者随访期间粪便标本中病毒的检出情况。结果咽拭子和痰液单次配对采样检测，咽拭子中病毒核酸检出率为46.15%，痰液中检出率为50.00%。第二次配对采样检测，咽拭子中病毒核酸检出率为25.93%，痰液中检出率为46.30%，两种标本检出率差异有统计学意义(P<0.05)。6例出院随访患者的采样检测，咽拭子或痰液检测均为阴性，而粪便标本检测均出现阳性，且最长可在患者体内存在52 d。结论在新型冠状病毒肺炎患者康复后期，随着临床症状的好转，呼吸道症状逐渐消失，病毒可能从呼吸道进入胃肠道，且在康复患者体内长时间存在并随粪便排出。建议在新型冠状病毒肺炎患者出院前进行核酸检测时，可考虑增加不同部位标本取样，以降低漏检率，避免假阴性病例的出现。

简介：摘要随着2019新型冠状病毒病(2019 novel coronavirus disease, COVID-19)疫情的迅速蔓延及全国各地的流行病学统计和诊治经验的积累，目前已明确癌症患者由于免疫力低下，感染2019新型冠状病毒以及感染后预后不良的风险增加。妇科肿瘤占女性恶性肿瘤的18.6%，是妇科常见疾病，因疫情持续中断诊治可能会影响疾病最终转归。部分妇科肿瘤患者出现癌性发热、乏力、纳差、腹痛、白细胞偏低等，与COVID-19难以鉴别诊断，甚至延误治疗，并增加医护人员感染的风险。为了最大程度保护妇科肿瘤患者及医务人员的健康和安全，我们将COVID-19疫情期间妇科肿瘤患者的分类管理和临床诊治的经验和措施进行系统梳理，总结成文供参考。

简介：摘要目的对北京市各家医院在COVID-19疫情期间放疗工作与防控措施的调查研究进行经验总结，为下一步工作提供参考。方法本次调查采用电子调查问卷，通过北京医学会放射肿瘤治疗学分会和北京医师协会放射治疗专科医师(技师)分会的各位委员对各家医院放疗科进行调查问卷的填写与反馈。结果截止2020年4月10日全北京市开展放疗工作的40家医院全部反馈了调查问卷，除1家医院因非疫情原因暂停治疗外，各医院均采取了相应的防控措施，并持续进行放疗工作。所有工作人员与收治患者均未发现COVID-19感染病例。结论COVID-19疫情期间，各医院高度重视，优化临床收治流程，采取合理的防控措施；在满足疫情防控的基础上，坚持开展放疗工作，满足广大肿瘤患者的治疗需求。

简介：摘要国际病毒分类委员会的冠状病毒研究小组通过系统进化分析，认为新型冠状病毒是SARS冠状病毒（SARS-CoV）的姊妹病毒，同属于SARS相关冠状病毒（SARSr-CoV），将新型冠状病毒命名为"SARS-CoV-2"，同时，世界卫生组织也将"新型冠状病毒肺炎"重新命名为冠状病毒病-19（COVID-19），我们分析其病理变化及发病机制可能与SARS有相似之处。因此，根据我们的4例SARS尸体解剖发现及研究结果对COVID-19的病理变化及其发病机制等问题进行初步探讨，供病理及临床工作者参考。

简介：摘要目的调查2019新型冠状病毒病(COVID-19)疫情期间四川省各地市级医院肿瘤患者的诊治情况，分析疫情对肿瘤患者住院和治疗的影响，为不同省份的医疗机构开展肿瘤患者的诊治提供参考。方法对四川省地市级医院通过问卷表的形式进行调查。采用描述性统计方法分析疫情期间四川省地市级医院肿瘤科患者的诊治情况。结果调查了四川省37家地市级大中型医院，其中三级甲等医院占78.4%。在调查医院中，疫情一级响应后，肿瘤科患者住院指数和放疗指数<1的医院占比分别为83.7%和93.1%。化疗正常进行或推迟时间≤1周的医院占54.1%，放疗在春节假期后正常进行或延迟时间≤1周的医院占89.7%。疫情二级响应后，肿瘤科患者和放疗患者较一级响应后上升的医院占比分别为78.4%和79.3%。结论在国务院、四川省委省政府、四川省卫健委、各地市级卫健委的指导下，各医疗机构和肿瘤科临床一线医护人员的共同努力下，COVID-19疫情期间大部分肿瘤患者在四川省各地市级医院得到积极有效的治疗。

简介：AbstractForecasting the COVID-19 confirmed cases, deaths, and recoveries demands time to know the severity of the novel coronavirus. This research aims to predict all types of COVID-19 cases (verified people, deaths, and recoveries) from the deadliest 3rd wave data of the COVID-19 pandemic in Bangladesh. We used the official website of the Directorate General of Health Services as our data source. To identify and predict the upcoming trends of the COVID-19 situation of Bangladesh, we fit the Auto-Regressive Integrated Moving Average (ARIMA) model on the data from Mar. 01, 2021 to Jul. 31, 2021. The finding of the ARIMA model (forecast model) reveals that infected, deaths, and recoveries number will have experienced exponential growth in Bangladesh to October 2021. Our model reports that confirmed cases and deaths will escalate by four times, and the recoveries will improve by five times at a later point in October 2021 if the trend of the three scenarios of COVID-19 from March to July lasts. The prediction of the COVID-19 scenario for the next three months is very frightening in Bangladesh, so the strategic planner and field-level personnel need to search for suitable policies and strategies and adopt these for controlling the mass transmission of the virus.

简介：无

简介：无

简介：摘要自2019年底，中国武汉暴发新型冠状病毒（2019-nCoV）肺炎以来，展现了我国对未知病原鉴定的能力。目前，报道的传播途径主要通过呼吸道飞沫和间接接触传播为主，其他传播途径还有待证实。本文讨论了2019-nCoV的可能传播途径，现有研究证实呼吸道的飞沫传播和接触传播是主要途径，粪口途径传播可能性比较大，气溶胶传播、泪液传播和母婴传播途径仍有待证实，为2019-nCoV的防控及公众防护提供参考依据。

简介：AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.

简介：无

简介：无

简介：AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1

简介：摘要由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019年冠状病毒疾病（COVID-19）已经在全球多个国家引起大流行，该病毒传染性强、致死率高，部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性；不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物，疫情控制需依赖新型冠状病毒疫苗的接种，如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习，展现目前相关研究的进展。

简介：摘要Coronavirus disease (COVID-19), the infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported on December 31, 2019. Because it has only been studied for just over three months, our understanding of this disease is still incomplete, particularly regarding its sequelae and long-term outcomes. Moreover, very little has been written about the rehabilitation needs of patients with COVID-19 after discharge from acute care. The objective of this report is to answer the question " What rehabilitation services do survivors of COVID-19 require？" The question was asked within the context of a subacute hospital delivering geriatric inpatient and outpatient rehabilitation services. Three areas relevant to rehabilitation after COVID-19 were identified. First, details of how patients may present have been summarized, including comorbidities, complications from an intensive care unit stay with or without intubation, and the effects of the virus on multiple body systems, including those pertaining to cardiac, neurological, cognitive, and mental health. Second, I have suggested procedures regarding the design of inpatient rehabilitation units for COVID-19 survivors, staffing issues, and considerations for outpatient rehabilitation. Third, guidelines for rehabilitation (physiotherapy, occupational therapy, speech-language pathology) following COVID-19 have been proposed with respect to recovery of the respiratory system as well as recovery of mobility and function. A thorough assessment and an individualized, progressive treatment plan which focuses on function, disability, and return to participation in society will help each patient to maximize their function and quality of life. Careful consideration of the rehabilitation environment will ensure that all patients recover as completely as possible.

简介：AbstractCoronavirus disease 2019 (COVID-19) is a newly emerged infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The number of COVID-19 cases is continuously increasing and no effective drugs or vaccines are currently available. Accurate and efficient diagnostic testing methods are desperately needed for the detection of SARS-CoV-2 and antiviral antibodies in infected individuals. Various assay techniques, including nucleic acid tests [eg, polymerase chain reaction (PCR), reverse transcription-PCR, real-time loop-mediated isothermal amplification, and CRISPR-Cas-based detection], serological tests [eg, immunoglobulin (Ig)A, IgM/G], imaging tests (eg, computed tomography and positron-emission tomography), and nanoparticle-based detections have been reported for COVID-19 diagnosis. This review aims to present the current diagnostic tools for SARS-CoV-2 and their performance characteristics to inform the appropriate selection of diagnostic and surveillance technologies at optimal testing times. We also describe the advantages of detection using combined nucleic acid and imaging tests, or serological testing and point-of-care diagnostics. Developing reliable protein biomarkers targeting the conserved proteins of SARS-CoV-2 rather than IgA, IgM, or IgG would be useful to manage SARS-CoV-2.

简介：无

简介：AbstractSince the outbreak of the novel coronavirus in Wuhan, China, as obstetricians, we also face great challenges. We need to identify pregnant patients with 2019 coronavirus disease infection timely, and give them appropriate treatment in order to obtain a good maternal and infant prognosis. Here, we would like to share a case and provide some suggestions on how to screen, diagnose and treat pregnant women with 2019 coronavirus disease infection during the outbreak.

简介：无